Apellis Pharmaceuticals Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Dec. 13, 2017 (GLOBE NEWSWIRE) --

What:
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company, developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Cedric Francois, MD, PhD, founder and chief executive officer of Apellis, will ring the Closing Bell.

Where:
Nasdaq MarketSite - 4 Times Square - 43^rd & Broadway - Broadcast Studio

When:
Thursday, December 14, 2017 - 3:45 p.m. to 4:00 p.m. ET

Apellis Pharmaceuticals, Inc. Media Contact:
Tully Nicholas, Denterlein on behalf of Apellis
tnicholas@denterlein.com
617.482.0042

Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://ift.tt/1ejh9f4.

For photos from ceremonies and events, please visit our Instagram page:
http://ift.tt/1kkvASh

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://ift.tt/T4ODTg

Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
http://ift.tt/NYKeUb or http://ift.tt/1gnW0EA

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://ift.tt/2doY7Jl and click on the market close of your choice.

About Apellis:
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. The company recently announced the closing of its initial public offering on November 13, 2017.

About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://ift.tt/1ySbdC8

-NDAQA-